Manufacturing Samsung Biologics: geographic diversification is a sound business decision Pharmaceutical TechnologySamsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.Read full story pharminent July 22, 2026 (Last updated: July 23, 2026) Pharmaceutical Technology Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015. Read full story Post navigation Previous: Repligen builds in cell therapy with $1.5bn BioLife takeoverNext: Speciality versus diversity: the four-way CDMO race in outsourced HPAPI manufacturing Related Stories Manufacturing BMS banks on Texas for $2.3bn multi-modal manufacturing facility pharminent August 11, 2026 Manufacturing AsymBio to secure $184m to support growth in biologics manufacturing pharminent August 5, 2026 Manufacturing Lilly and Resilience invest $750M in diabetes and obesity drug device supply pharminent July 31, 2026
